Risks and benefits of tamoxifen therapy

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 21-23

  Assikis, Vasilios J ^a   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CONFERENCE PAPER; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; HUMAN; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIPID METABOLISM; RISK ASSESSMENT; TAMOXIFEN;

EID: 8244231275     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Lobo RA, Pickar JH, Wild RA, et al: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987-995, 1994.
2. Bilimoria MM, Assikis VJ, Jordan VC: Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2:140-150, 1996.
3. Weiss NS, Ure CL, Ballard JH, et al: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198, 1980.
4. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol 4:5A-10A, 1988.
5. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br J Med 303:435-437, 1991.
6. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993.
7. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238, 1985.
8. Assikis VJ, Neven P, Jordan VC, et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer Part A 32A:1464-1476, 1996
9. Malfetano J: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients Gynecol Oncol 39:82-84, 1990.
10. Magriples U, Naftolin F, Schwartz PE, et al: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485-490, 1993.
11. National Cancer Institute: SEER Cancer Statistics Review 1973-1990, Document #93-2789, Bethesda, Maryland, National Cancer Institute, 1993.
12. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the NSABP B-14, J Natl Cancer Inst 86:527-537, 1994.
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992.